Bristol-Myers Squibb Acquires Amylin Pharmaceuticals and Releases Second Quarter Results
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the second quarter of 2012 highlighted by the planned strategic acquisition of Amylin Pharmaceuticals and the presentation of important clinical data from the Company’s immuno-oncology pipeline. The Company also adjusted its GAAP EPS guidance range and confirmed its non-GAAP EPS guidance range for 2012.
“We have been preparing for the expected loss of exclusivity of Plavix and Avapro/Avalide for a number of years and I am pleased with our company’s progress as we look to the future,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “With the growth of a large number of key products from across our portfolio, the promising data from our immuno-oncology franchise presented at ASCO and the innovative planned acquisition of Amylin we are building a strong foundation for success.”
SECOND QUARTER FINANCIAL RESULTS
Bristol-Myers Squibb posted second quarter 2012 net sales of $4.4 billion, a decrease of 18% compared to the same period a year ago, following the U.S. patent expiration of Avapro/Avalidein March 2012 and Plavix in May 2012. Excluding Plavix and Avapro/Avalide, net sales grew by 8% compared to the second quarter of 2011.
U.S. net sales decreased 27% to $2.6 billion in the quarter compared to the same period a year ago following the U.S. patent expiration of Avapro/Avalideand Plavix. International net sales decreased 1% to $1.9 billion.
Gross margin as a percentage of net sales was 72.0% in the quarter compared to 72.7% in the same period a year ago.
Marketing, selling and administrative expenses decreased 3% to $1 billion in the quarter.
Advertising and product promotion spending decreased 11% to $224 million in the quarter.
Research and development expenses increased 4% to $962 million in the quarter.
The effective tax rate on earnings before income taxes was 23.7% in the quarter, compared to 27.0% in the second quarter last year.
The Company reported net earnings attributable to Bristol-Myers Squibb of $645 million, or $0.38 per share, in the quarter compared to $902 million, or $0.52 per share, a year ago.
The Company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $808 million, or $0.48 per share, in the second quarter, compared to $971 million, or $0.56 per share, for the same period in 2011. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.
Cash, cash equivalents and marketable securities were $8.8 billion, with a net cash position of $3.3 billion, as of June 30, 2012.
$17.8 Million was the cost of a test project for an inflatable home for astronauts in outer space. 30% of U.S. military commanders have been relieved from duty in the past eight years due to sexual related offenses including adultery, harassment and improper relationships. $4.6 Million was paid at an Arizona auction for the original…
iFOSTER EXPANDS COMPUTER, TABLET, CELLULAR SERVICE AND BROADBAND ACCESS TO THE NATION’S FOSTER CARE COMMUNITY Truckee, CA – May 8, 2012 — iFoster announced plans to enhance its delivery of 75,000 low-cost computers and laptops and 4,500 affordable broadband connections to the nation’s foster care community by providing computer training, discounted cellular service and tablets…
Cheryl McCants recently accepted recognition for her 30+ years of professional excellence from Marquis Who’s Who as well as new positions within the New York and New Jersey Minority Supplier Development Council
149 air-traffic-control towers at small U.S. airports will be closed by the Federal Aviation Authority due to sequestration cuts. $100K is the start-up grant offered by the “Bill & Melinda Gates Foundation” to design “the next-generation condom.” 72% is the increase in U.S. craft-beer exports between 2012 and 2011. www.eimpactconsulting.com Your strategic communication, marketing, brand management and public relations partner….
Media Contacts: Cheryl McCants, cmccants@eimpactconsulting.com, 646-872-2377 Jazelle Hunt, jhunt@eimpactconsulting.com, 202-642-2452 MEDIA ALERT Ribbon Cutting: Central Ward Community Storefront for Newark Entrepreneurs Open for Business All small business retail incubators are now open for business, one in each Ward Mayor Ras J. Baraka and the Newark…